000182408 001__ 182408
000182408 005__ 20240229145718.0
000182408 0247_ $$2doi$$a10.1007/s00392-022-02119-7
000182408 0247_ $$2pmid$$apmid:36289063
000182408 0247_ $$2ISSN$$a0300-5860
000182408 0247_ $$2ISSN$$a1435-1285
000182408 0247_ $$2ISSN$$a1861-0684
000182408 0247_ $$2ISSN$$a1861-0692
000182408 0247_ $$2altmetric$$aaltmetric:142096254
000182408 037__ $$aDKFZ-2022-02629
000182408 041__ $$aEnglish
000182408 082__ $$a610
000182408 1001_ $$aKolwelter, Julie$$b0
000182408 245__ $$aThe SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial.
000182408 260__ $$aBerlin$$bSpringer$$c2023
000182408 3367_ $$2DRIVER$$aarticle
000182408 3367_ $$2DataCite$$aOutput Types/Journal article
000182408 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1675341870_2342
000182408 3367_ $$2BibTeX$$aARTICLE
000182408 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182408 3367_ $$00$$2EndNote$$aJournal Article
000182408 500__ $$a2023 Jan;112(1):134-144
000182408 520__ $$aSodium-glucose co-transporter 2 (SGLT2) inhibitors have cardiovascular protective properties in addition to the metabolic effects and represent a cornerstone of treating patients with chronic heart failure (CHF). We hypothesised that empagliflozin reduces tissue sodium content in patients with CHF.In a double-blind, randomised (2:1), placebo-controlled, parallel-group, clinical trial, 74 patients with NYHA class II-III CHF and an ejection fraction of 49% or less received empagliflozin 10 mg once daily or placebo for 3 months. In each patient, tissue sodium content of the lower leg was assessed non-invasively by sodium-MRI (23Na-MRI) at baseline, after 1 and 3 months of treatment.After 1 and 3 months treatment with empagliflozin (n = 48), a significant decrease in skin sodium content was observed (1 month: 22.8 ± 6.1 vs. 21.6 ± 6.0 AU, p = 0.039; 3 months: 22.9 ± 6.1 vs. 21.6 ± 6.1 AU, p = 0.013), while there was no change in muscle sodium and muscle water content. In direct comparison, the change in skin sodium content between baseline and 3 months was - 1.3 ± 3.5 AU in the empagliflozin group versus 0.6 ± 3.5 AU in the placebo group (p for between-group difference = 0.022). No significant difference regarding change in muscle sodium and in muscle water content was observed after 3 months treatment between the two groups.This trial showed a significant decrease in skin sodium content after 1 and 3 months of treatment with empagliflozin. The decrease in skin sodium content may reflect a decrease in subclinical micro-oedema or/and in non-osmotic bound tissue sodium, both reported to impair left ventricular function.NCT03128528 ( http://www.gov ).25th April 2017.
000182408 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000182408 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182408 650_7 $$2Other$$aChronic heart failure
000182408 650_7 $$2Other$$aEmpagliflozin
000182408 650_7 $$2Other$$aMagnetic resonance imaging
000182408 650_7 $$2Other$$aSGLT2 inhibitor
000182408 650_7 $$2Other$$aSodium
000182408 650_7 $$2Other$$aTissue sodium content
000182408 7001_ $$aKannenkeril, Dennis$$b1
000182408 7001_ $$aLinz, Peter$$b2
000182408 7001_ $$aJung, Susanne$$b3
000182408 7001_ $$0P:(DE-He78)054fd7a5195b75b11fbdc5c360276011$$aNagel, Armin M$$b4$$udkfz
000182408 7001_ $$aBosch, Agnes$$b5
000182408 7001_ $$aOtt, Christian$$b6
000182408 7001_ $$aBramlage, Peter$$b7
000182408 7001_ $$aNöh, Lisa$$b8
000182408 7001_ $$aSchiffer, Mario$$b9
000182408 7001_ $$aUder, Michael$$b10
000182408 7001_ $$aAchenbach, Stephan$$b11
000182408 7001_ $$aSchmieder, Roland E$$b12
000182408 773__ $$0PERI:(DE-600)2218331-0$$a10.1007/s00392-022-02119-7$$n1$$p134-144$$tClinical research in cardiology$$v112$$x0300-5860$$y2023
000182408 909CO $$ooai:inrepo02.dkfz.de:182408$$pVDB
000182408 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)054fd7a5195b75b11fbdc5c360276011$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000182408 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000182408 9141_ $$y2022
000182408 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-26$$wger
000182408 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-26
000182408 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-26
000182408 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-26
000182408 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000182408 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000182408 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000182408 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-26
000182408 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000182408 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-26
000182408 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-26
000182408 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN RES CARDIOL : 2022$$d2023-08-26
000182408 9201_ $$0I:(DE-He78)E020-20160331$$kE020$$lE020 Med. Physik in der Radiologie$$x0
000182408 980__ $$ajournal
000182408 980__ $$aVDB
000182408 980__ $$aI:(DE-He78)E020-20160331
000182408 980__ $$aUNRESTRICTED